17 completed, 2 unknown, 1 active not recruiting. 20 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 20 | Completed 17, Unknown 2, Active not recruiting 1 |
| Phase 2 | 2 | Completed 1, Unknown 1 |
Follow Febuxostat: new trials by email Literature Review of Febuxostat trials Research Report on Febuxostat
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Tigulixostat (IBI128) vs Febuxostat in Gout Febuxostat, Tigulixostat - Gout | Phase 3 | Active not recruiting | Innovent Biologics Technology Limited (Shanghai R&D Center) | 600 | 2026-03-17 | 2026-09-01 |
| Clinical Trial of HR091506 Tablets in Treatment of Gout With Hyperuricemia in Adults HR091506 tablets + placebo of febuxostat tablets, febuxostat tablets + placebo of HR091506 tablets - Gout With Hyperuricemia in Adults | Phase 3 | Unknown | Jiangsu HengRui Medicine Co., Ltd. | 434 | 2024-06-01 | 2024-05-16 |
| Phase II/III Study of AR882 Capsules Compared to Febuxostat Tablets in Patients with Primary Gout and Hyperuricemia Febuxostat 20MG Tablets, Febuxostat 20MG Placebo, AR882 25MG - Primary Gout, Hyperuricemia | Phase 2 / Phase 3 | Unknown | Guangzhou Ruianbo Pharmaceutical Technology Co., Ltd | 636 | 2024-04-22 | 2024-09-19 |
| Clinical Study of HR091506 Tablets in Treatment of Gout With Hyperuricemia in Adults HR091506 tablets + placebo of febuxostat tablets, febuxostat tablets + placebo of HR091506 tablets - Gout With Hyperuricemia in Adults | Phase 3 | Completed | Jiangsu HengRui Medicine Co., Ltd. | 765 | 2023-12-14 | 2025-10-02 |
| A Therapeutic Confirmatory Study of Epaminurad Versus Febuxostat in Gout Patients Epaminurad 6 mg, Epaminurad 9 mg, Febuxostat 40 mg - Gout | Phase 3 | Completed | JW Pharmaceutical | 612 | 2023-03-21 | 2026-05-04 |
| A Study to Evaluate Efficacy of Dotinurad and Febuxostat for the Treatment of Participants With Gout Dotinurad, Febuxostat, Dotinurad Matched Placebo - Gout | Phase 3 | Completed | Eisai Co., Ltd. | 451 | 2021-12-21 | 2025-07-30 |
| Febuxostat-Controlled, Double-Blind, Comparative Study of FYU-981 in Hyperuricemia With or Without Gout FYU-981, Febuxostat - Hyperuricemia With or Without Gout | Phase 3 | Completed | Mochida Pharmaceutical Company, Ltd. | 203 | 2018-01-09 | 2018-09-24 |
| Effect of Febuxostat on Endothelial Dysfunction in Hemodialysis Patients. Febuxostat, Placebo - Endothelial Dysfunction, Endstage Renal Disease | Phase 2 / Phase 3 | Completed | Ain Shams University | 57 | 2016-08-01 | 2018-01-02 |
| Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout Febuxostat IR, Febuxostat XR, Febuxostat placebo - Gout | Phase 3 | Completed | Takeda | 1790 | 2014-04-01 | 2016-11-03 |
| Lesinurad and Febuxostat Combination Extension Study in Gout lesinurad, febuxostat - Gout | Phase 3 | Completed | Ardea Biosciences, Inc. | 196 | 2013-03-01 | 2018-01-30 |
| Febuxostat for Tumor Lysis Syndrome Prevention in Hematologic Malignancies Febuxostat, Allopurinol - Tumor Lysis Syndrome | Phase 3 | Completed | Menarini Group | 346 | 2012-10-01 | 2014-11-03 |
| Combination Treatment Study in Subjects With Tophaceous Gout With Lesinurad and Febuxostat Lesinurad, Placebo, Febuxostat - Tophaceous Gout | Phase 3 | Completed | Ardea Biosciences, Inc. | 330 | 2012-01-01 | 2016-05-26 |
| Safety and Efficacy of Oral Febuxostat in Subjects With Gout Febuxostat, Allopurinol - Gout | Phase 3 | Completed | Xijing Hospital | 504 | 2011-07-01 | 2016-02-03 |
| A Study to Evaluate Safety and Efficacy of Oral Febuxostat in Patients With Gout febuxostat, Allopurinol - Gout | Phase 3 | Completed | Astellas Pharma Taiwan, Inc. | 109 | 2011-03-01 | 2014-10-29 |
| Cardiovascular Safety of Febuxostat and Allopurinol in Participants With Gout and Cardiovascular Comorbidities (CARES) Febuxostat, Allopurinol - Cardiovascular Disease | Phase 3 | Completed | Takeda | 6198 | 2010-04-23 | 2018-06-14 |
| Efficacy and Safety of Oral Febuxostat in Participants With Gout Febuxostat, Allopurinol - Gout | Phase 3 | Completed | Takeda | 2269 | 2007-02-01 | 2012-02-02 |
| Phase III Trial of Febuxostat in Korea Gout Patients Febuxostat - Gout | Phase 3 | Completed | SK Chemicals Co., Ltd. | 181 | 2006-08-01 | 2009-01-13 |
| Allopurinol Versus Febuxostat in Subjects Completing the Phase 3 Trials C02-009 or C02-010 Febuxostat, Allopurinol - Gout | Phase 3 | Completed | Takeda | 1086 | 2003-07-01 | 2010-07-27 |
| Phase 3, Febuxostat, Allopurinol and Placebo-Controlled Study in Gout Subjects. Febuxostat, Allopurinol, Placebo - Gout | Phase 3 | Completed | Takeda | 1072 | 2003-02-01 | 2012-02-02 |
| Febuxostat Versus Allopurinol Control Trial in Subjects With Gout Febuxostat, Allopurinol - Gout | Phase 3 | Completed | Takeda | 760 | 2002-07-01 | 2012-02-02 |
Gout (13) · Hyperuricemia (4) · Cardiovascular Diseases (1) · Leukemia (1) · Lymphoma (1) · Myocardial Infarction (1) · Stroke (1) · Tumor Lysis Syndrome (1)
Takeda (6) · Ardea Biosciences, Inc. (2) · Jiangsu HengRui Medicine Co., Ltd. (2) · Ain Shams University (1) · Astellas Pharma Taiwan, Inc. (1) · Eisai Co., Ltd. (1) · Guangzhou Ruianbo Pharmaceutical Technology Co., Ltd (1) · Innovent Biologics Technology Limited (Shanghai R&D Center) (1) · JW Pharmaceutical (1) · Menarini Group (1) · Mochida Pharmaceutical Company, Ltd. (1) · SK Chemicals Co., Ltd. (1) · Xijing Hospital (1)
United States (5) · China (4) · Australia (2) · Canada (2) · New Zealand (2) · Poland (2) · Switzerland (2) · Japan (1) · Mexico (1) · South Korea (1) · Taiwan (1)
Angela Capriati, MD, PhD (1) · Bin Liu, M.D. (1) · Chris Storgard, MD (1) · Haiwang Ji, M.D. (1) · Hong Liu, M.D. (1) · Jianqin Wang, M.D. (1) · Jinying Lin, M.D. (1) · Kazuki Furuno (1) · Michele Spina, MD (1) · Nihar Bhakta, MD (1) · Peng Liu, M.D. (1) · Shenren Chen, M.D. (1) · Won Park, MD (1)
PMID 21353107, PMID 22052584, PMID 18600509, PMID 16339094, PMID 18975369, PMID 19286847, PMID 20370912, PMID 21849262, PMID 22132950, PMID 22316106, PMID 22436129, PMID 22795277, PMID 23683134, PMID 26013187, PMID 26216382, PMID 28597604, PMID 29527974, PMID 30073793, PMID 30616614, PMID 35536764, PMID 35835008